CLPT News & Events

ClearPoint Neuro announced plans to enter the focused ultrasound market and demonstrated successful intravenous delivery of tracers across the blood-brain barrier in a preclinical model using a prototype system built in partnership with the SONOCARELAB at Sungkyunkwan University. "This milestone has been nearly four years in the making, and demonstrates our continuous pursuit to be the most complete neuro navigation and therapy enabling company in the world," said Joe Burnett, president and CEO. "By leveraging our 15 years of neuro navigation software development, and by deploying focused ultrasound using our planned robotic platform in a traditional OR setting, we believe the ClearPoint and SONOCARELAB solution will fit perfectly into our four-pillar growth strategy."

ClearPoint Neuro announced that the Velocity Alpha MR High Speed Surgical Drill System has received CE Marking in addition to the existing FDA 510(k) clearance in the United States.

The company expects cost synergies resulting from the acquisition of IRRAS to contribute to a reduction in cash burn in the second half of 2026 and believes the asset integration could potentially be cash neutral for the full year 2027. "We continue to believe that these four pillars will each contribute double digit growth in 2026, and represent a solid foundation on which to build our commercial cell and gene therapy delivery business in the future," said CEO Joe Burnett.

Reports Q1 revenue $12.1M vs. $8.5M last year. Neurosurgery navigation, therapy and access revenue increased 80% to $5.9M, driven by additional revenues from sales of the IRRAflow product and the introduction of 3.0 operating room navigation software. "Our team is off to a strong start in 2026 with forward progress across our entire four-pillar growth strategy," said CEO Joe Burnett.